Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | Q9HBH1 | 1/20 | 0.61 | |
| ▸ | SSTR3 | P32745 | 1/20 | 0.54 |
| ▸ | MMP3 | P08254 | 3/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.39 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386663 | 1.00 | PDF (0.61) | PDFSSTR3MMP3MMP1MMP9 | |
| SCHEMBL27750016 | 1.00 | PDF (0.61) | PDFSSTR3MMP3MMP1MMP9 | |
| Hydrochloric Acid SCHEMBL8853773 | 0.99 | PDF (0.60) | PDFSSTR3MMP3MMP1MMP9 | |
| Hydrochloric Acid SCHEMBL3481900 | 0.99 | PDF (0.60) | PDFSSTR3MMP3MMP1MMP9 | |
| Hydrochloric Acid SCHEMBL3482618 | 0.99 | PDF (0.60) | PDFSSTR3MMP3MMP1MMP9 | |
| SCHEMBL8000347 | 0.94 | PDF (0.67) | PDFSSTR3MMP2SMN1; SMN2LMNA | |
| SCHEMBL27695845 | 0.90 | PDF (0.48) | PDFMMP3MMP1SMN1; SMN2LMNA | |
| SCHEMBL27695847 | 0.90 | PDF (0.48) | PDFMMP3MMP1SMN1; SMN2LMNA | |
| Hydrochloric Acid SCHEMBL27484221 | 0.89 | PDF (0.47) | PDFMMP3MMP1SMN1; SMN2LMNA | |
| SCHEMBL5318843 | 0.88 | PDF (0.65) | PDFSSTR3MMP3MMP1MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4740954-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA, INC. (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-3638369-B1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | AZITRA INC (US) | 2026-04-21 | — | — | US | disclosed |
| US-20240218049-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF NETHERTON SYNDROME WITH LEKTI EXPRESSING RECOMBINANT MICROBES | AZITRA INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-11773154-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | AZITRA INC (US) | 2023-10-03 | — | — | US | disclosed |
| WO-2022272132-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTION | AZITRA INC (US) | 2022-12-29 | — | — | WO | disclosed |
| EP-4055040-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF CANCER WITH LEKTI | AZITRA, INC. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-4054713-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF SKIN DISEASES AND DISORDERS WITH LEKTI | AZITRA, INC. (US) | 2022-09-14 | — | — | EP | disclosed |
| WO-2020240446-A1 | MEDICAL DEVICES WITH REDUCED THROMBOGENICITY | Heart Research Institute Ltd. (AU) | 2020-12-03 | — | — | WO | disclosed |
| EP-2508611-B1 | Process for production of triprenyl phenol compounds | TMS CO LTD (JP) | 2019-05-08 | — | — | EP | disclosed |
| WO-1996024849-A1 | DIOXETANE COMPOUNDS FOR THE CHEMILUMINESCENT DETECTION OF PROTEASES, METHODS OF USE AND KITS THEREFORE | TROPIX, INC. (US) | 1996-08-15 | — | — | WO | disclosed |
| EP-0692968-A1 | UROKINASE PLASMINOGEN ACTIVATOR FRAGMENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1996-01-24 | — | — | EP | disclosed |
| WO-1995029189-A1 | FACTOR Xa INHIBITORS | SELECTIDE CORPORATION (US) | 1995-11-02 | — | — | WO | disclosed |
| WO-1994022464-A1 | UROKINASE PLASMINOGEN ACTIVATOR FRAGMENTS | THE GENERAL HOSPITAL CORPORATION (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0498883-A4 | 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0498883-A1 | 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-08-19 | — | — | EP | disclosed |
| WO-1992004432-A1 | 3-SUBSTITUTED AND 3,3-DISUBSTITUTED 4-OXORETINOIC ACIDS AND THEIR ESTERS | SOUTHERN RESEARCH INSTITUTE (US) | 1992-03-19 | — | — | WO | disclosed |
| EP-0332678-A4 | MICRO-SIZE FIBRINOLYTIC PLASMIN. | UNIV NORTHWESTERN (US) | 1990-06-27 | — | — | EP | disclosed |
| US-4851346-A | PLASMIOGEN ACTIVATOR; ANTITUMOR AGENT | MILES INC. (US) | 1989-07-25 | — | — | US | disclosed |
| WO-1989001336-A1 | MICRO-SIZE FIBRINOLYTIC PLASMIN | NORTHWESTERN UNIVERSITY (US) | 1989-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12606610-B2 | Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes | CUTA, TMPRSS11D, KLK5 | PDF 2001/4885SSTR3 3918/4885MMP3 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.